Formycon Begins Biosimilar Ustekinumab Trial

Phase I Trial Announcement Comes Shortly After NeuClone

 
• By Dave Wallace

Formycon has become the latest firm to announce a Phase I trial for a proposed biosimilar ustekinumab rival to Janssen’s Stelara, following hot on the heels of NeuClone.

Race_Track
Formycon’s Phase I trial has got off the blocks at around the same time as NeuClone’s • Source: Shutterstock

More from Biosimilars

More from Products